Skip to main content
SpringerLink
Log in

Medroxyprogesterone Acetate in Cancer Cachexia

  • Chapter
Cachexia and Wasting: A Modern Approach

  • 2119 Accesses

Abstract

For a long time the use of testosterone-derivative drugs (nandrolone decanoate and others) has been indicated for patients with cancer anorexiacachexia syndrome (CACS) on the basis of a truly protein anabolic effect [1], but the above drugs have a limited use because of some severe sideeffects (liver damage, endocrine effects).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kochakian CD (1976) II Metabolic effects. In: Kochakian CD (ed) Anabolic Steroids. Springer Verlag, Berlin, pp 5–72

    Google Scholar 

  2. Mantovani G, Macciò A, Massa E, Madeddu C (2001) Managing cancer-related anorexia/cachexia. Drugs 61:499–514

    Article  PubMed  CAS  Google Scholar 

  3. Pannuti F, Martoni A, Camaggi CM et al (1982) High dose medroxyprogesterone acetate in oncology. History, clinical use and pharmacokinetics In: Cavalli F, McGuire WL, Pannuti F (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Amsterdam, pp 5–43

    Google Scholar 

  4. Pannuti F, Burroni P, Fruet F et al (1980) Anabolizing and antipain effect of the short-term treatment with medroxyprogesterone acetate (MAP) at high oral doses in oncology. Panminerva Med 22:149

    PubMed  CAS  Google Scholar 

  5. Lelli G, Angelelli B, Giambiasi ME et al (1983) The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 15:561–568

    Article  PubMed  CAS  Google Scholar 

  6. Lelli G, Angelelli B, Zanichelli L et al (1984) The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemioterapia 3:327–329

    PubMed  CAS  Google Scholar 

  7. Mantovani G, Macciò A, Lai P et al (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25(Suppl 6):45–52

    PubMed  CAS  Google Scholar 

  8. Kurebayashi J, Yamamoto S, Otsuki T et al (1999) Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 79:631–636

    Article  PubMed  CAS  Google Scholar 

  9. Downer S, Joel S, Albright A et al (1993) A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67:1102–1105

    PubMed  CAS  Google Scholar 

  10. Kornek GV, Schenk T, Ludwig H et al (1996) Placebo-controlled trial of medroxyprogesterone acetate in gastrointestinal malignancies and cachexia. Onkologie 19:164–168

    Article  Google Scholar 

  11. Neri B, Garosi VL, Intini C (1997) Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 8:459–465

    Article  PubMed  CAS  Google Scholar 

  12. Simons J, Aaronson NK, Vansteenkiste JFetal (1996) Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non hormone sensitive cancer: a placebo controlled multicenter study. J Clin Oncol 14:1077–1084

    PubMed  CAS  Google Scholar 

  13. Simons JP, Schols AM, Hoefnagels JM et al (1988) Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer. Cancer 82:553–560

    Article  Google Scholar 

  14. Gagnon B, Bruera E (1998) A review of the drug treatment of cachexia associated with cancer. Drugs 55:675–688

    Article  PubMed  CAS  Google Scholar 

  15. Maltoni M, Nanni O, Scarpi E et al (2001) High-dose progestins for the treatment of cancer anorexiacachexia syndrome. A systematic review of randomized clinical trials. Ann Oncol 12:289–300

    Article  PubMed  CAS  Google Scholar 

  16. Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology-Pathology, Clinical Oncology Unit, University Hospital of Ferrara, Ferrara, Italy

    Giorgio Lelli, Benedetta Urbini, Daniela Scapoli & Germana Gilli

Authors
  1. Giorgio Lelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benedetta Urbini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Scapoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Germana Gilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, University of Cagliari, Cagliari, Italy

    Giovanni Mantovani

  2. Department of Clinical Cardiology, Imperial College, NHLI, London, UK

    Stefan D. Anker

  3. Department of Cardiology Charité, Applied Cachexia Research, Campus Virchow-Klinikum, Berlin, Germany

    Stefan D. Anker

  4. Department of Behavioral Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    Akio Inui

  5. GRECC, VA Medical Center and Division of Geriatric Medicine, Saint Louis University, St. Louis, MO, USA

    John E. Morley

  6. Department of Clinical Medicine, University of Rome, La Sapienza, Rome, Italy

    Filippo Rossi Fanelli

  7. Department of Infectious Diseases, IRCCS S.Matteo Polyclinic, University of Pavia, Pavia, Italy

    Daniele Scevola

  8. Bone Marrow and Blood Stem Cell Transplantation Program, Center for Lymphoma and Myeloma, New York Presbyterian Hospital/Weill Medical Center, New York, NY, USA

    Michael W. Schuster

  9. Department of Medicine-Geriatrics, University of New York at Stony Brook VAMC, Northport, NY, USA

    Shing-Shing Yeh

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Lelli, G., Urbini, B., Scapoli, D., Gilli, G. (2006). Medroxyprogesterone Acetate in Cancer Cachexia. In: Mantovani, G., et al. Cachexia and Wasting: A Modern Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-0552-5_63

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0552-5_63

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0471-9

  • Online ISBN: 978-88-470-0552-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation